Bio-Techne Corp
TECH65.850USD
+2.360+3.72%
Cierre 11/25, 16:00（ET）Cotizaciones retrasadas 15 min
10.26BCap. mercado
131.57P/E TTM
Más Datos de Bio-Techne Corp Compañía
Bio-Techne Corporation is a global life sciences company providing tools and bioactive reagents for the research and clinical diagnostic communities. The Company's products assist scientific investigations into biological processes and the nature and progress of specific diseases. The Company, in partnership with Wilson Wolf, is creating products such as media and cytokines that are specifically tailored to G-Rex Bioreactors. Its segments include Protein Sciences and Diagnostics and Genomics. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. This segment also includes proteomic analytical tools, both manual and automated. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, exosome-based molecular diagnostic assays, and tissue biopsy analysis.
Información de Bio-Techne Corp
Símbolo de cotizaciónTECH
Nombre de la empresaBio-Techne Corp
Fecha de salida a bolsaFeb 09, 1989
Director ejecutivoMr. Kim Kelderman
Número de empleados3100
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 09
Dirección614 Mckinley Pl N E
CiudadMINNEAPOLIS
Bolsa de valoresNASDAQ Global Select Consolidated
PaísUnited States of America
Código postal55413
Teléfono16123792956
Sitio Webhttps://www.bio-techne.com/
Símbolo de cotizaciónTECH
Fecha de salida a bolsaFeb 09, 1989
Director ejecutivoMr. Kim Kelderman
Ejecutivos de Bio-Techne Corp
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Dr. Matthew F. Mcmanus
Dr. Matthew F. Mcmanus
President - Diagnostics and Spatial Biology
President - Diagnostics and Spatial Biology
4.74K
+169.49%
Mr. Shane Bohnen
Mr. Shane Bohnen
Senior Vice President, General Counsel, Corporate Secretary
Senior Vice President, General Counsel, Corporate Secretary
4.38K
--
Dr. Judith V. Klimovsky, M.D.
Dr. Judith V. Klimovsky, M.D.
Independent Director
Independent Director
3.78K
+76.56%
Mr. James T. (Jim) Hippel
Mr. James T. (Jim) Hippel
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
--
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. John L. Higgins
Mr. John L. Higgins
Independent Director
Independent Director
66.88K
+2.51%
Mr. Kim Kelderman
Mr. Kim Kelderman
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
48.66K
-4.52%
Mr. Robert V. (Bob) Baumgartner, CPA
Mr. Robert V. (Bob) Baumgartner, CPA
Independent Chairman of the Board
Independent Chairman of the Board
46.50K
+3.66%
Dr. Joseph D. (Joe) Keegan, Ph.D.
Dr. Joseph D. (Joe) Keegan, Ph.D.
Independent Director
Independent Director
15.41K
+11.91%
Dr. Rupert J. Vessey, Ph.D.
Dr. Rupert J. Vessey, Ph.D.
Independent Director
Independent Director
10.99K
+17.55%
Ms. Julie L. Bushman
Ms. Julie L. Bushman
Independent Director
Independent Director
8.78K
+22.99%
Desglose de ingresos
Divisa: USDActualizado: lun., 6 de oct
Divisa: USDActualizado: lun., 6 de oct
FY2025
FY2025Q4
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2021
FY2020
FY2019
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Por regiónUSD
Nombre
Ganancia
Proporción
United States
683.23M
56.02%
EMEA, excluding U.K
266.31M
21.83%
Greater China
100.46M
8.24%
APAC, excluding Greater China
77.26M
6.33%
United Kingdom
54.83M
4.50%
Rest of World
37.55M
3.08%
Por negocio
Por región
Por negocioUSD
Nombre
Ganancia
Proporción
Consumables
972.29M
79.72%
Instruments
112.09M
9.19%
Service
111.57M
9.15%
Royalty
23.69M
1.94%
Estadísticas de accionistas
Actualizado: dom., 16 de nov
Actualizado: dom., 16 de nov
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Otro
72.73%
Accionistas
Accionistas
Proporción
The Vanguard Group, Inc.
11.48%
BlackRock Institutional Trust Company, N.A.
5.64%
State Street Investment Management (US)
3.69%
Wellington Management Company, LLP
3.28%
Atlanta Capital Management Company, L.L.C.
3.17%
Otro
72.73%
Tipos de accionistas
Accionistas
Proporción
Investment Advisor
57.86%
Investment Advisor/Hedge Fund
34.00%
Hedge Fund
8.05%
Bank and Trust
2.18%
Research Firm
1.96%
Pension Fund
1.33%
Sovereign Wealth Fund
1.24%
Individual Investor
0.28%
Insurance Company
0.24%
Participación institucional
Actualizado: mié., 1 de oct
Actualizado: mié., 1 de oct
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q3
1198
161.18M
103.53%
-7.34M
2025Q2
1209
165.25M
105.41%
-730.33K
2025Q1
1245
168.10M
107.22%
+1.54M
2024Q4
1233
162.21M
102.61%
-6.39M
2024Q3
1205
159.40M
100.49%
-10.21M
2024Q2
1207
160.52M
101.86%
-12.24M
2024Q1
1216
162.56M
103.40%
-7.57M
2023Q4
1229
159.70M
100.98%
-3.97M
2023Q3
1217
156.41M
98.84%
-7.93M
2023Q2
1213
155.36M
98.68%
-4.04M
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
The Vanguard Group, Inc.
18.40M
11.82%
-60.83K
-0.33%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
8.79M
5.65%
-512.26K
-5.50%
Jun 30, 2025
State Street Investment Management (US)
5.86M
3.76%
-671.30K
-10.28%
Jun 30, 2025
Atlanta Capital Management Company, L.L.C.
4.29M
2.76%
+573.23K
+15.41%
Jun 30, 2025
Geode Capital Management, L.L.C.
4.06M
2.61%
-30.89K
-0.75%
Jun 30, 2025
Invesco Capital Management LLC
3.24M
2.08%
+274.96K
+9.28%
Jun 30, 2025
Neuberger Berman, LLC
2.50M
1.61%
-526.06K
-17.38%
Jun 30, 2025
T. Rowe Price Associates, Inc.
8.62M
5.53%
-2.53M
-22.68%
Jun 30, 2025
Ver más
ETFs relacionados
Actualizado: jue., 6 de nov
Actualizado: jue., 6 de nov
Nombre
Proporción
Global X Genomics & Biotechnology ETF
3.95%
Invesco Biotechnology & Genome ETF
2.62%
Invesco S&P 500 Equal Weight Health Care ETF
1.79%
VanEck Biotech ETF
1.63%
Neuberger Berman Small-Mid Cap ETF
1.58%
Hilton Small-MidCap Opportunity ETF
1.55%
Thrivent Small-Mid Cap ESG ETF
1.44%
American Century Mid Cap Growth Impact ETF
1.39%
WisdomTree BioRevolution Fund
1.22%
iShares Health Innovation Active ETF
1.2%
Ver más
Global X Genomics & Biotechnology ETF
Proporción3.95%
Invesco Biotechnology & Genome ETF
Proporción2.62%
Invesco S&P 500 Equal Weight Health Care ETF
Proporción1.79%
VanEck Biotech ETF
Proporción1.63%
Neuberger Berman Small-Mid Cap ETF
Proporción1.58%
Hilton Small-MidCap Opportunity ETF
Proporción1.55%
Thrivent Small-Mid Cap ESG ETF
Proporción1.44%
American Century Mid Cap Growth Impact ETF
Proporción1.39%
WisdomTree BioRevolution Fund
Proporción1.22%
iShares Health Innovation Active ETF
Proporción1.2%
Dividendos
Un total de
250.90M
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Feb 05, 2025
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 28, 2025 going ex on Feb 14, 2025
Feb 17, 2025
Feb 28, 2025
Feb 14, 2025
Oct 30, 2024
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 22, 2024 going ex on Nov 08, 2024
Nov 11, 2024
Nov 22, 2024
Nov 08, 2024
Aug 07, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Aug 30, 2024 going ex on Aug 19, 2024
Aug 19, 2024
Aug 30, 2024
Aug 19, 2024
May 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 24, 2024 going ex on May 10, 2024
May 13, 2024
May 24, 2024
May 10, 2024
Feb 01, 2024
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 26, 2024 going ex on Feb 09, 2024
Feb 12, 2024
Feb 26, 2024
Feb 09, 2024
Oct 31, 2023
TECH.NB Final Cash Dividend of gross USD 0.08 paid on Nov 24, 2023 going ex on Nov 09, 2023
Nov 10, 2023
Nov 24, 2023
Nov 09, 2023
Aug 08, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Sep 01, 2023 going ex on Aug 17, 2023
Aug 18, 2023
Sep 01, 2023
Aug 17, 2023
May 03, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on May 26, 2023 going ex on May 12, 2023
May 15, 2023
May 26, 2023
May 12, 2023
Feb 02, 2023
TECH.NB Interim Cash Dividend of gross USD 0.08 paid on Feb 27, 2023 going ex on Feb 10, 2023
Feb 13, 2023
Feb 27, 2023
Feb 10, 2023
Nov 01, 2022
TECH.NB Final Cash Dividend of gross USD 0.32 paid on Nov 28, 2022 going ex on Nov 10, 2022
Nov 14, 2022
Nov 28, 2022
Nov 10, 2022
Ver más
División de acciones
Fecha
Tipo
Relación
Nov 01, 2022
Split
1→4
Fecha
Tipo
Relación
Nov 01, 2022
Split
1→4
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Bio-Techne Corp?
Los cinco principales accionistas de Bio-Techne Corp son:
The Vanguard Group, Inc. posee 18.40M acciones, lo que representa el 11.82% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.79M acciones, lo que representa el 5.65% del total de acciones.
State Street Investment Management (US) posee 5.86M acciones, lo que representa el 3.76% del total de acciones.
Atlanta Capital Management Company, L.L.C. posee 4.29M acciones, lo que representa el 2.76% del total de acciones.
Geode Capital Management, L.L.C. posee 4.06M acciones, lo que representa el 2.61% del total de acciones.
The Vanguard Group, Inc. posee 18.40M acciones, lo que representa el 11.82% del total de acciones.
BlackRock Institutional Trust Company, N.A. posee 8.79M acciones, lo que representa el 5.65% del total de acciones.
State Street Investment Management (US) posee 5.86M acciones, lo que representa el 3.76% del total de acciones.
Atlanta Capital Management Company, L.L.C. posee 4.29M acciones, lo que representa el 2.76% del total de acciones.
Geode Capital Management, L.L.C. posee 4.06M acciones, lo que representa el 2.61% del total de acciones.
¿Cuáles son los tres principales tipos de accionista de Bio-Techne Corp?
Los tres principales tipos de accionista de Bio-Techne Corp son:
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
The Vanguard Group, Inc.
BlackRock Institutional Trust Company, N.A.
State Street Investment Management (US)
¿Cuántas instituciones poseen acciones de Bio-Techne Corp (TECH)?
A fecha de 2025Q3, 1198 instituciones poseen acciones de Bio-Techne Corp, con un valor de mercado combinado de aproximadamente 161.18M, lo que representa el 103.53% del total de acciones. En comparación con el 2025Q2, el accionariado institucional ha aumentado en -1.88%.
¿Cuál es la mayor fuente de ganancias de Bio-Techne Corp?
El FY2025, el segmento empresarial Consumables generó la ganancia más alta para Bio-Techne Corp, ascendiendo a 972.29M y representando el 79.72% de la ganancia total.
